MKI67 and neoplasm: The assessment of the individual recurrence risk needs to be guided by a combination of multifactorial clinical, pathological and genomic predictive and prognostic factors for both the patient and the tumour, such as tumour stage, histopathological grading, proliferative indices such as Ki67, age, menopausal status, comorbidities, and multigene test recurrence scores.